Dr. March is Professor of Medicine, Physiology and Biomedical Engineering at the Indiana University School of Medicine and Krannert Institute of Cardiology. He is the Director of the Indiana Center for Vascular Biology and Medicine, and holds the Cryptic Masons Chair in Vascular Biology and Medicine.

Dr. March's research has led from fundamental concepts to clinically useful approaches, resulting in the development of several novel technologies. These innovations involving cardiovascular devices as well as device/drug and device/gene combination approaches, have led to the issuance of 40 worldwide (19 US) patents with other pending.

He invented and patented a device called Closer, a suture-mediated closure device that is used to close the arterial hole following a heart catheterization. This device allows a patient to "walk off the table" after a catheterization without requiring prolonged bed rest. The company that developed this technology was acquired in 1999 by Abbott Vascular, an affiliate of Abbott Laboratories, for $680 million, and the Closer approach is now used in 500,000 patients worldwide annually.

Dr. March is currently focusing his efforts on research exploring approaches using both adult stem cells and novel devices to treat peripheral artery disease, acute and chronic ischemic heart disease and atherosclerosis. Most recently, working with Dr. Michael Murphy, he has overseen the completion of the first FDA-approved USA trial testing stem cells for peripheral vascular disease.

Dr. March has published more than 75 manuscripts and edited the first book dedicated to cardiovascular gene transfer. He has served as a scientific advisor to numerous pharmaceutical, biotechnology, and medical device companies.